Genetic determinants of response to aspirin: Appraisal of 4 candidate genes

Thrombosis Research

Volumn 128, Issue 1, 2011, Pages 47-53

  Lordkipanidzé, Marie ^a,b   Diodati, Jean G ^a,b   Palisaitis, Donald A ^a,b   Schampaert, Erick ^a,b   Turgeon, Jacques ^a,c   Pharand, Chantal ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Aspirin; Genetics; Platelets; Responsiveness

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ALPHA2B BETA3 INTEGRIN PROTEIN; ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYTOCHROME P450 5A1 PROTEIN; P2RY1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CAUCASIAN; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETICS; GENOTYPE; HUMAN; MAJOR ADVERSE CARDIOVASCULAR AND CEREBROVASCULAR EVENT; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE AGGREGATION;

AGED; ASPIRIN; CORONARY ARTERY DISEASE; CYCLOOXYGENASE 1; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MALE; PLATELET AGGREGATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RECEPTORS, PURINERGIC P2Y1; THROMBOXANE-A SYNTHASE;

EID: 79958048562     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.02.019     Document Type: Article

References (52)

1. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials. Lancet 2009;373:1849-60.
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
3. Awtry EH, Loscalzo J. Aspirin. Circulation 2000;101:1206-18.
4. Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007;28:1702-8. (Pubitemid 47227104)
5. Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007;115:3156-64. (Pubitemid 47012230)
6. Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007;153:175-81. (Pubitemid 46096871)
7. Peace A, McCall M, Tedesco T, Kenny D, Conroy RM, Foley D, et al. The role of weight and enteric coating on aspirin response in cardiovascular patients. J Thromb Haemost 2010;8:2323-5.
8. Christiaens L, Macchi L, Herpin D, Coisne D, Duplantier C, Allal J, et al. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. Thromb Res 2003;108:115-9.
9. Kawasaki T, Ozeki Y, Igawa T, Kambayashi J-I. Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 2000;31:591-5. (Pubitemid 30131641)
10. Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G, et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002;107:45-9. (Pubitemid 35284424)
11. Kranzhofer R, Ruef J. Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA(1/2) polymorphism. Platelets 2006;17:163-9. (Pubitemid 43791628)
12. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 2001;88:756-62. (Pubitemid 32429970)
13. Santos MT, Valles J, Lago A, Tembl J, Sanchez E, Moscardo A, et al. Residual platelet thromboxane A2 and prothrombotic effects of erythrocytes are important determinants of aspirin resistance in patients with vascular disease. J Thromb Haemost 2008;6:615-21. (Pubitemid 351404928)
14. Lordkipanidzé M, Diodati JG, Turgeon J, Schampaert E, Palisaitis DA, Pharand C. Platelet count, not oxidative stress, may contribute to inadequate platelet inhibition by aspirin. Int J Cardiol 2010;143:43-50.
15. Zimmermann N, Wenk A, Kim U, Kienzle P, Weber AA, Gams E, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003;108:542-7. (Pubitemid 36961167)
16. Andrioli G, Minuz P, Solero P, Pincelli S, Ortolani R, Lussignoli S, et al. Defective platelet response to arachidonic acid and thromboxane A(2) in subjects with Pl (A2) polymorphism of beta(3) subunit (glycoprotein IIIa). Br J Haematol 2000;110:911-8.
17. Szczeklik A, Undas A, Sanak M, Frolow M, Wegrzyn W. Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa. Br J Haematol 2000;110:965-7.
18. Undas A, Brummel K, Musial J, Mann KG, Szczeklik A. PlA2 polymorphism of beta-3 integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 2001;104:2666-72. (Pubitemid 33108131)
19. Macchi L, Christiaens L, Brabant S, Sorel N, Ragot S, Allal J, et al. Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5 T kozak (GP Ib[alpha]) polymorphisms. J Am Coll Cardiol 2003;42:1115-9. (Pubitemid 37108603)
20. Pamukcu B, Oflaz H, Nisanci Y. The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis. Am Heart J 2005;149:675-80.
21. Papp E, Havasi V, Bene J, Komlosi K, Czopf L, Magyar E, et al. Glycoprotein IIIA gene (PlA) polymorphism and aspirin resistance: is there any correlation? Ann Pharmacother 2005;39:1013-8.
22. Jefferson BK, Foster JH, McCarthy JJ, Ginsburg G, Parker A, Kottke-Marchant K, et al. Aspirin resistance and a single gene. Am J Cardiol 2005;95:805-8. (Pubitemid 40332670)
23. Maree AO, Curtin RJ, Chubb A, Dolan C, Cox D, O'Brien J, et al. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 2005;3: 2340-5. (Pubitemid 41727215)
24. Faraday N, Yanek LR, Mathias R, Herrera-Galeano JE, Vaidya D, Moy TF, et al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 2007;115:2490-6. (Pubitemid 46763222)
25. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000;69:145-82.
26. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120. (Pubitemid 28231490)
27. Ulrich CM, Bigler J, Sibert J, Greene EA, Sparks R, Carlson CS, et al. Cyclooxygenase 1 (COX1) polymorphisms in African-American and Caucasian populations. Hum Mutat 2002;20:409-10.
28. Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: Effects on response to aspirin. Clin Pharmacol Ther 2003;73:122-30. (Pubitemid 36158493)
29. Hillarp A, Palmqvist B, Lethagen S, Villoutreix BO, Mattiasson I. Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke. Thromb Res 2003;112:275-83. (Pubitemid 38373757)
30. Lepantalo A, Mikkelsson J, Resendiz JC, Viiri L, Backman JT, Kankuri E, et al. Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost 2006;95:253-9.
31. Faraday N, Herrera-Galeano JE, Yanek L, Moy TF, Bray PF, Becker D, et al. Genetic variation in cyclooxygenase-dependent platelet activation is an uncommon cause of diminished aspirin responsiveness (abstract). Circulation 2006;114:II-71.
32. Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 2008;66:222-32.
33. Ulrich CM, Carlson CS, Sibert J, Poole EM, Yu JH, Wang LH, et al. Thromboxane synthase (TBXAS1) polymorphisms in African-American and Caucasian populations: evidence for selective pressure. Hum Mutat 2005;26:394-5.
34. Chevalier D, Lo-Guidice JM, Sergent E, Allorge D, Debuysere H, Ferrari N, et al. Identification of genetic variants in the human thromboxane synthase gene (CYP5A1). Mutat Res 2001;432:61-7. (Pubitemid 32144949)
35. Kimouli M, Gourvas V, Konstantoudaki X, Basta M, Miyakis S, Spandidos DA. The effect of an exon 12 polymorphism of the human thromboxane synthase (CYP5A1) gene in stroke patients. Med Sci Monit 2009;15:BR30-5.
36. Gachet C. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. Pharmacol Ther 2005;108:180-92. (Pubitemid 41528788)
37. Hetherington SL, Singh RK, Lodwick D, Thompson JR, Goodall AH, Samani NJ. Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP. Arterioscler Thromb Vasc Biol 2005;25:252-7. (Pubitemid 40054285)
38. Newman PJ, Derbes RS, Aster RH. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 1989;83:1778-81. (Pubitemid 19124140)
39. Garcia-Ribes M, Gonzalez-Lamuno D, Hernandez-Estefania R, Colman T, Pocovi M, Delgado-Rodriguez M, et al. Polymorphism of the platelet glycoprotein IIIa gene in patients with coronary stenosis. Thromb Haemost 1998;79:1126-9. (Pubitemid 28297159)
40. Mikkelsson J, Perola M, Laippala P, Penttila A, Karhunen PJ. Glycoprotein IIIa Pl(A1/A2) polymorphism and sudden cardiac death. J AmColl Cardiol 2000;36:1317-23.
41. Burke J, Kraft WK, Greenberg HE, Gleave M, Pitari GM, VanBuren S, et al. Relationship of arachidonic acid concentration to cyclooxygenase-dependent human platelet aggregation. J Clin Pharmacol 2003;43:983-9. (Pubitemid 37022742)
42. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-5. (Pubitemid 36315537)
43. Wenaweser P, Dorffler-Melly J, Imboden K, Windecker S, Togni M, Meier B, et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005;45:1748-52. (Pubitemid 40779850)
44. Perneby C, Granstrom E, Beck O, Fitzgerald D, Harhen B, Hjemdahl P. Optimization of an enzyme immunoassay for 11-dehydro-thromboxane B(2) in urine: comparison with GC-MS. Thromb Res 1999;96:427-36.
45. Scott BT, Hasstedt SJ, Bovill EG, Callas PW, Valliere JE, Wang L, et al. Characterization of the human prostaglandin H synthase 1 gene (PTGS1): exclusion by genetic linkage analysis as a second modifier gene in familial thrombosis. Blood Coagul Fibrinolysis 2002;13:519-31.
46. Feng D, Lindpaintner K, Larson MG, Rao VS, O'Donnell CJ, Lipinska I, et al. Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 1999;19:1142-7. (Pubitemid 29177367)
47. Lunetta KL. Genetic Association Studies. Circulation 2008;118:96-101.
48. Fontana P, Remones V, Reny JL, Aiach M, Gaussem P. P2Y1 gene polymorphism and ADP-induced platelet response. J Thromb Haemost 2005;3:2349-50.
49. Lev EI, Patel RT, Guthikonda S, Lopez D, Bray PF, Kleiman NS. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thromb Res 2007;119:355-60.
50. Gonzalez-Conejero R, Rivera J, Corral J, Acuna C, Guerrero JA, Vicente V. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke 2005;36:276-80.
51. Lee CR, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. Clin Pharmacol Ther 2008;83:52-60.
52. Michelson AD. Platelet function testing in cardiovascular diseases. Circulation 2004;110:e489-93.